- cafead Jun 30, 2020 at 10:42: AM
via Mereo BioPharma canceled its expected IPO last year in a reverse merger with OncoMed and now is filling up a number of key research posts with execs from the company.
Today, Mereo appointed John Lewicki, Ph.D., as its new chief scientific officer and Ann Kapoun, Ph.D., as senior vice president of translational R&D. Both worked at cancer biotech OncoMed before, now merged into Mereo, with both also having worked on anti-TIGIT oncology hopeful etigilimab before the 2019 union.
article source
Today, Mereo appointed John Lewicki, Ph.D., as its new chief scientific officer and Ann Kapoun, Ph.D., as senior vice president of translational R&D. Both worked at cancer biotech OncoMed before, now merged into Mereo, with both also having worked on anti-TIGIT oncology hopeful etigilimab before the 2019 union.
article source